Portage Biotech Net Worth
Portage Biotech Net Worth Breakdown | PRTG |
Portage Biotech Net Worth Analysis
Portage Biotech's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Portage Biotech's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Portage Biotech's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Portage Biotech's net worth analysis. One common approach is to calculate Portage Biotech's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Portage Biotech's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Portage Biotech's net worth. This approach calculates the present value of Portage Biotech's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Portage Biotech's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Portage Biotech's net worth. This involves comparing Portage Biotech's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Portage Biotech's net worth relative to its peers.
Enterprise Value |
|
To determine if Portage Biotech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Portage Biotech's net worth research are outlined below:
| Portage Biotech generated a negative expected return over the last 90 days | |
| Portage Biotech has high historical volatility and very poor performance | |
| Net Loss for the year was (75.34 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Portage Biotech currently holds about 21.18 M in cash with (14.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.25. | |
| Portage Biotech has a frail financial position based on the latest SEC disclosures | |
| Roughly 51.0% of the company outstanding shares are owned by corporate insiders |
Portage Biotech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Portage Biotech. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Portage Biotech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 29th of July 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of July 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Portage Biotech Target Price Consensus
Portage target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Portage Biotech's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Hold |
Most Portage analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Portage stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Portage Biotech, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationPortage Biotech Target Price Projection
Portage Biotech's current and average target prices are 4.20 and 10.00, respectively. The current price of Portage Biotech is the price at which Portage Biotech is currently trading. On the other hand, Portage Biotech's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Portage Biotech Market Quote on 20th of March 2025
Target Price
Analyst Consensus On Portage Biotech Target Price
Know Portage Biotech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Portage Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Portage Biotech backward and forwards among themselves. Portage Biotech's institutional investor refers to the entity that pools money to purchase Portage Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Princeton Global Asset Management Llc | 2024-12-31 | 8.0 | Bnp Paribas Arbitrage, Sa | 2024-12-31 | 7.0 | Connective Capital Management Llc | 2024-12-31 | 0.0 | The Toronto-dominion Bank | 2024-09-30 | 0.0 | Carolinas Wealth Consulting Llc | 2024-09-30 | 0.0 | Renaissance Technologies Corp | 2024-12-31 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 0.0 | Virtu Financial Llc | 2024-12-31 | 0.0 | Ieq Capital, Llc | 2024-09-30 | 0.0 | Lakeview Capital Partners, Llc | 2024-12-31 | 19.3 K | Citadel Advisors Llc | 2024-12-31 | 15.4 K |
Follow Portage Biotech's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.99 M.Market Cap |
|
Project Portage Biotech's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (8.72) | (8.28) | |
| Return On Capital Employed | (3.35) | (3.52) | |
| Return On Assets | (8.72) | (8.28) | |
| Return On Equity | (16.86) | (17.70) |
When accessing Portage Biotech's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Portage Biotech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Portage Biotech's profitability and make more informed investment decisions.
Evaluate Portage Biotech's management efficiency
Portage Biotech has return on total asset (ROA) of (0.1545) % which means that it has lost $0.1545 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.9889) %, meaning that it created substantial loss on money invested by shareholders. Portage Biotech's management efficiency ratios could be used to measure how well Portage Biotech manages its routine affairs as well as how well it operates its assets and liabilities. The Portage Biotech's current Return On Tangible Assets is estimated to increase to -8.28. The current Return On Capital Employed is estimated to decrease to -3.52. The Portage Biotech's current Other Current Assets is estimated to increase to about 3.2 M, while Total Assets are projected to decrease to roughly 8.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.19 | 0.18 | |
| Net Current Asset Value | -443.4 K | -465.6 K | |
| Tangible Book Value Per Share | 0.19 | 0.18 | |
| Enterprise Value Over EBITDA | (13.90) | (14.60) | |
| Price Book Value Ratio | 64.32 | 97.43 | |
| Enterprise Value Multiple | (13.90) | (14.60) | |
| Price Fair Value | 64.32 | 97.43 | |
| Enterprise Value | 347.8 M | 365.1 M |
Understanding the operational decisions made by Portage Biotech management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Portage Biotech Corporate Filings
6K | 13th of March 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 31st of January 2025 Other Reports | ViewVerify | |
F3 | 14th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
| 23rd of August 2024 Other Reports | ViewVerify |
Portage Biotech Earnings Estimation Breakdown
The calculation of Portage Biotech's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Portage Biotech is estimated to be 0.0 with the future projection ranging from a low of 0.0 to a high of 0.0. Please be aware that this consensus of annual earnings estimates for Portage Biotech is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.00 Lowest | Expected EPS | 0.00 Highest |
Portage Biotech Earnings Projection Consensus
Suppose the current estimates of Portage Biotech's value are higher than the current market price of the Portage Biotech stock. In this case, investors may conclude that Portage Biotech is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Portage Biotech's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 0 | 37.14% | -24.2 | 0.0 | -68.17 |
Portage Biotech Earnings per Share Projection vs Actual
Actual Earning per Share of Portage Biotech refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Portage Biotech predict the company's earnings will be in the future. The higher the earnings per share of Portage Biotech, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Portage Biotech Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Portage Biotech, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Portage Biotech should always be considered in relation to other companies to make a more educated investment decision.Portage Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Portage Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-06-06 | 2024-03-31 | -0.22 | -24.2 | -23.98 | 10900 | ||
2024-02-28 | 2023-12-31 | -0.27 | 0.01 | 0.28 | 103 | ||
2023-11-28 | 2023-09-30 | -0.28 | -0.29 | -0.01 | 3 | ||
2023-08-30 | 2023-06-30 | -0.24 | -0.33 | -0.09 | 37 | ||
2023-05-31 | 2023-03-31 | -0.29 | -5.36 | -5.07 | 1748 | ||
2023-03-01 | 2022-12-31 | -0.23 | -0.44 | -0.21 | 91 | ||
2022-11-29 | 2022-09-30 | -0.29 | -0.06 | 0.23 | 79 | ||
2022-08-28 | 2022-06-30 | -0.3 | -0.13 | 0.17 | 56 | ||
2022-06-01 | 2022-03-31 | -0.28 | -0.56 | -0.28 | 100 | ||
2022-02-24 | 2021-12-31 | -0.27 | -0.26 | 0.01 | 3 | ||
2021-11-23 | 2021-09-30 | -0.25 | -0.22 | 0.03 | 12 | ||
2021-07-29 | 2021-06-30 | -0.21 | -0.25 | -0.04 | 19 |
Portage Biotech Corporate Management
| MD MBA | CEO Board | Profile | |
| Allan CPA | Chief Officer | Profile | |
| Adam Melero | Controller | Profile | |
| EunJae CPA | Chief Officer | Profile | |
| Robert Kramer | Chief Officer | Profile | |
| Brian Wiley | Chief Officer | Profile | |
| Andrea Park | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Portage Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Portage Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.